Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center presents the final overall survival data from the phase 3 FLAURA2 study of osimertinib plus chemotherapy in epidermal growth factor receptor (EGFR)-mutated advanced non–small cell lung cancer (NSCLC), at more than 47.5 months versus approximately 38 months for osimertinib alone, and asks how the panel handles cross-trial comparison. Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute says he starts with the caveat that comparing separate trials is unreliable but that clinicians are left with no other option, and concludes that the 2 intensified regimens are largely comparable on efficacy, leaving selection to toxicity and to practical realities in a patient’s life. Matthew Gumbleton, MD, PhD, of Huntsman Cancer Institute shares the published papers with interested patients and notes it is easier to back off a regimen for toxicity than to switch for progression.
